Last quarter (Q3 2023), Landos Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Landos Biopharma's net income was $-5.86M. See Landos Biopharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	$ 18.00M	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 9.60M	$ -40.56M	$ -56.82M	$ 30.68M	$ 13.29M	$ 5.93M
Operating Income	$ -22.63M	$ -40.56M	$ -56.82M	$ -30.68M	$ -13.29M	$ -5.93M
Net Non Operating Interest Income Expense	$ 1.61M	$ 1.26M	$ 412.00K	$ 455.00K	$ -144.00K	$ -4.00K
Other Income Expense	$ -134.00K	$ -168.00K	$ -17.77M	$ 77.00K	$ -33.00K	$ -106.00K
Pretax Income	$ -21.05M	$ -39.28M	$ -38.42M	$ -30.14M	$ -13.47M	$ -6.04M
Tax Provision	-	-	$ -77.10M	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -20.84M	$ -39.11M	$ -38.66M	$ -30.14M	$ -13.47M	$ -6.04M
Basic EPS	$ -2.16	$ -0.98	$ -1.02	$ -0.77	$ -0.58	$ -0.26
Diluted EPS	$ -1.79	$ -0.98	$ -1.02	$ -0.77	$ -0.58	$ -0.26
Basic Average Shares	$ 117.51M	$ 40.25M	$ 37.56M	$ 39.16M	$ 23.10M	$ 23.10M
Diluted Average Shares	$ 117.51M	$ 40.25M	$ 37.56M	$ 39.16M	$ 23.10M	$ 23.10M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 9.60M	$ -40.56M	$ -56.82M	$ 30.68M	$ 13.29M	$ 5.93M
Net Income From Continuing And Discontinued Operation	$ -20.98M	$ -39.11M	$ -38.66M	$ -30.14M	$ -13.47M	$ -6.04M
Normalized Income	-	-	-	$ -30.22M	$ -13.43M	$ -5.94M
Interest Expense	-	-	-	$ 0.00	$ 304.00K	$ 4.00K
EBIT	$ -24.70M	$ -39.28M	$ -38.42M	$ -30.68M	$ -13.16M	$ -6.04M
EBITDA	$ -24.56M	$ -37.53M	$ -37.05M	$ -30.54M	$ -13.06M	$ -5.96M

Currency in USD

Landos Biopharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing